SCHEMBL5532075

SCHEMBL5532075

C#Cc1ccc(NC(=O)c2cc(OC)ccc2NC(=O)c2ccc(N=CN3CCC(C(=O)OCC)CC3)cc2F)cc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
F10 P00742 6/20 0.44
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
KCNH2 Q12809 1/20 0.41
MAPT P10636 1/20 0.40
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
POLB P06746 3/20 0.38
TDP1 Q9NUW8 1/20 0.37
TP53 P04637 1/20 0.37
GAA P10253 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
GPR6 P46095 1/20 0.36
PTPN11 Q06124 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5532069 1.00 F10 (0.44) F10KMT2AMEN1KCNH2MAPT
SCHEMBL5531794 0.94 KMT2A (0.43) F10KMT2AKCNH2MAPTKDM4E
SCHEMBL5531795 0.94 KMT2A (0.43) F10KMT2AKCNH2MAPTKDM4E
SCHEMBL5527883 0.94 F10 (0.48) F10GPR6
SCHEMBL5527882 0.94 F10 (0.48) F10GPR6
SCHEMBL5535637 0.91 F10 (0.45) F10KMT2AMEN1KCNH2MAPT
SCHEMBL5535644 0.91 F10 (0.45) F10KMT2AMEN1KCNH2MAPT
SCHEMBL5530427 0.91 F10 (0.46) F10KMT2AMEN1KCNH2MAPT
SCHEMBL5530431 0.91 F10 (0.46) F10KMT2AMEN1KCNH2MAPT
SCHEMBL5532105 0.91 F10 (0.47) F10GPR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP claimed
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP claimed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US claimed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO claimed
US-7312235-B2 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP disclosed
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP disclosed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US disclosed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069250-A1 Benzamide inhibitors of factor Xa SERPINC1, TFPI, F12 F10 10/4885KMT2A 2096/4885MEN1 2370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.